Cypermethrin Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a synthetic pyrethroid ectoparasiticide supplied as a non-sterile active pharmaceutical ingredient for downstream formulation. Its chemical identity is (RS)-α-cyano-3-phenoxybenzyl (1RS)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate, CAS 52315-07-8, molecular formula C₂₂H₁₉Cl₂NO₃, and molecular weight 416.30 g/mol. The material is a racemic mixture of stereoisomers; the cis/trans ratio is a critical release parameter because insecticidal activity is not evenly distributed across all configurations. The product appears as a white to pale yellow crystalline solid or waxy semi-solid depending on isomer ratio and ambient temperature. Water solubility is low, typically less than 0.01 mg/L at 20 °C, while the log octanol-water partition coefficient is approximately 6.3. The listed dosage forms refer to formulation capability rather than an assertion that oral or parenteral cypermethrin products are regulatory-approved in all jurisdictions. No single harmonized compendial monograph governs this veterinary-grade API; commercial designations vary by manufacturer, and the release certificate is the controlling specification document. Manufacturers commonly align the material with FAO Specification 332/TC for technical cypermethrin while applying tighter chromatographic purity limits for veterinary use.

The main route of veterinary pharmacological action is disruption of voltage-gated sodium channels in arthropod neurons, causing prolonged depolarization and paralysis. Cypermethrin differs from organophosphate parasiticides in that it does not act primarily by acetylcholinesterase inhibition, and it differs from macrocyclic lactones in its rapid knockdown rather than sustained systemic activity. The API is primarily suitable for topical solution, pour-on, spray, dip, and environmental ectoparasiticide formulations. Tablet, injection, capsule, powder, granule, and premix use is constrained by solubility, stability, and regulatory pathway considerations. Published data for oral or injectable cypermethrin formulations in food-producing animals is limited, and the ingredient should not be assumed to be systemically bioavailable in all presented dosage forms without formulation-specific development.

When Tablet and Injection Dosage Forms Demand Solubility-Limited Processing

For tablet and capsule intermediates, the principal processing constraint is the hydrophobic character of cypermethrin. Aqueous granulation is generally unsuitable because the API is practically insoluble in water and undergoes ester hydrolysis at elevated pH. Formulations intended for dry blending should use prior particle-size reduction. Industrial batches frequently require jet milling or pin milling to bring the API from an as-received D90 above 150 µm down to a target D90 of ≤75 µm, with D50 in the range of 10–40 µm, as determined by laser diffraction according to ISO 13320:2020. This reduction improves content uniformity in low-dose tablet and capsule batches, where the API may represent less than 5% w/w of the total core weight. Direct compression without micronization is not recommended because cohesive agglomerates produce poor blend uniformity and variable dissolution behaviour in the non-aqueous media often required for compendial testing.

Tablet compression on rotary presses should maintain low precompression force, typically below 8 kN, and main compression force in the range of 10–15 kN. Higher force can induce sticking and picking because the API softens as the cis/trans isomer mixture approaches its melting range. Microcrystalline cellulose and lactose monohydrate are the most common bulking agents, but levels of hygroscopic excipients should be controlled because moisture above 2% w/w in the final blend can accelerate hydrolysis during storage. Disintegration testing according to USP <701> may not predict in vivo release for uncoated cypermethrin tablets because the API tends to remain adsorbed to hydrophobic tablet matrices; formulation-specific dissolution method development is required.

For injection solutions, aqueous vehicles are not feasible without substantial cosolvent incorporation. Propylene glycol, benzyl alcohol, and medium-chain triglycerides have been evaluated as non-aqueous or low-water carriers in experimental parenteral ectoparasiticide systems, but published data for specific cypermethrin injection formulations is limited. The pH of any aqueous-containing vehicle must remain at or below 6.5, with water content below 0.2% w/w where the API is in solution, to minimize ester hydrolysis. Sterile filtration through 0.22 µm membranes is possible only after complete dissolution in a compatible organic phase; residual moisture and undissolved crystalline material will clog membranes and reduce yield. Terminal sterilization by moist heat is not appropriate for alkaline or high-moisture formulations due to degradation, while dry heat may alter the stereoisomer distribution. These boundary conditions mean that injectable cypermethrin is not a simple reformulation of pour-on concentrates and requires separate stability evaluation.

The API in tablet and injection development should be protected from light and from contact with alkaline lubricants or buffer systems. Magnesium stearate at levels above 1.0% w/w can retard dissolution in hydrophobic matrices, while sodium starch glycolate and croscarmellose sodium behave differently in non-aqueous dissolution environments. For capsule filling on automatic dosator machines, powder bed bulk density should be maintained above 0.50 g/mL to avoid weight variation exceeding 4% RSD; roller compaction or slugging may be required before encapsulation. Batch records from production-scale attempts indicate that the largest source of failure is content uniformity drift during hopper discharge, caused by static charge on the micronized API. Use of colloidal silicon dioxide at 0.5–1.0% w/w and control of ambient relative humidity below 60% RH reduce this effect.

Powder and granule production with cypermethrin is generally achieved by spraying a concentrated organic solution of the API onto a porous carrier such as lactose monohydrate, corn cob meal, silica, or calcium carbonate-free clay. Low-shear ribbon blenders operating at 20–30 rpm for 15–25 minutes provide adequate distribution when the spray rate is kept between 0.2 L/min and 0.4 L/min per 100 kg carrier. Higher spray rates cause localized overwetting, clump formation, and residual solvent levels above compendial limits. Content uniformity should be verified according to USP <905> or equivalent pharmacopoeial method, with acceptance limits of 85.0–115.0% of label claim for individual units and relative standard deviation not more than 6.0%. Premix for feed application requires a conservative upper assay limit because segregation during pneumatic conveying can create zones of elevated cypermethrin concentration; geometric dilution with a double-cone blender is the minimum acceptable mixing operation.

Granulation with aqueous binders is not recommended. If a wet granulation step is unavoidable, a non-aqueous binder solution of povidone in isopropanol at 5–10% w/w polymer concentration is preferred. Dryer outlet temperature should remain below 50 °C to avoid thermal isomerization or loss of volatile impurities that complicate release testing. Residual isopropanol must comply with USP <467> residual solvent limits, typically not more than 0.5% w/w. Alkaline granulating agents such as calcium hydroxide or sodium bicarbonate are incompatible with cypermethrin and should not be included in the formulation, even at low concentrations.

What Distinguishes Cypermethrin from Permethrin and Deltamethrin in Veterinary Use?

Cypermethrin belongs to the α-cyano pyrethroid family, which distinguishes it from non-α-cyano permethrin in terms of insecticidal potency and environmental stability. The presence of the α-cyano group increases knock-down activity against certain arthropods but also alters the metabolic detoxification profile in host species. Cypermethrin is a mixture of eight stereoisomers, while permethrin is a mixture of four stereoisomers and deltamethrin is supplied as an enriched single-entity configuration. This stereochemical difference has practical formulation consequences: the cis/trans ratio in cypermethrin must be controlled within narrow limits to maintain batch-to-batch biological activity, whereas permethrin and deltamethrin have less variable isomer composition in their commercial forms.

The comparative table summarizes identity differences that are documented in public pesticide and pharmaceutical databases. The most operationally significant difference is not the molecular weight but the stereoisomer ratio control required for cypermethrin. Deltamethrin is more potent on a weight basis, so formulation concentrations are typically lower, while cypermethrin is often formulated at 1.0–5.0% w/w in topical veterinary products. Permethrin has historically been used in companion animal spot-on products with higher dermal safety margins, but cypermethrin remains widely used in livestock parasiticides where knock-down speed and residual activity on hair and hide are required. In solution formulations, cypermethrin exhibits greater crystallization tendency than permethrin at low temperatures, and the use of aromatic hydrocarbon co-solvents is sometimes necessary to prevent precipitation below 5 °C. Deltamethrin is frequently formulated as an emulsion concentrate, while cypermethrin pour-on formulations are commonly solvent-based or emulsifiable concentrates with the API dissolved in an aromatic or glycol ether carrier.

Another difference from permethrin is the higher mammalian toxicity of cypermethrin by the oral route, which is the basis for restricting tablet and capsule applications in food-producing species. The API should not be dry-blended into feed premixes without a verifiable safe concentration gradient and segregation control. Deltamethrin and cypermethrin share a similar susceptibility to alkaline hydrolysis, but the different molecular weights and partition coefficients affect their residue depletion profiles in milk and meat; residue monitoring therefore requires compound-specific analytical methods rather than class-level pyrethroid methods.

Regulatory Release Limits, Storage, and Incompatibility Boundaries

Release testing for veterinary-grade cypermethrin API should include chromatographic purity, isomer ratio, water content, residual solvents, and related substances. A typical manufacturer specification is presented in the compliance matrix below. The limits are illustrative of industrial practice but must be adjusted to the registered formulation and regional pharmacopoeial or VICH requirements.

Storage in sealed HDPE drums with a desiccant-lined closure is recommended at or below 25 °C and 60% RH. Retest dating is commonly set at 24 months when the API is stored in the original closed container; opened containers should be re-evaluated for water content before use because moisture ingress above 0.5% w/w can initiate slow ester cleavage. The API is incompatible with strong oxidizing agents, alkaline carriers, and lime-based feed additives. Contact with carbon steel or unlined galvanized equipment should be avoided where residual organic solvents are present because trace metal ions can catalyze degradation. Micronized material is static-prone and should be handled in grounded stainless-steel equipment. Formulation batches that exceed 40 °C during solvent removal may show a shift in cis/trans ratio, and such thermal excursions should trigger reanalysis before release. No conclusion is drawn here; the operational boundaries listed above define the viable processing envelope for this multi-dosage-form veterinary API.